Trial Profile
EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Albiglutide; Alogliptin; Dipeptidyl peptidase 4 inhibitors; Dulaglutide; Exenatide; Glucagon like peptide 1 receptor agonists; Linagliptin; Liraglutide; Lixisenatide; Saxagliptin; Semaglutide; Sitagliptin
- Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMPRISE; EMPRISE United States
- Sponsors Boehringer Ingelheim
- 13 Jul 2023 Planned End Date changed from 30 Jun 2022 to 31 Dec 2024.
- 13 Jul 2023 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2024.
- 28 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2022.